Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Redhill Biophrma ADR (RDHL)

Redhill Biophrma ADR (RDHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,475
  • Shares Outstanding, K 4,543
  • Annual Sales, $ 8,040 K
  • Annual Income, $ -8,270 K
  • EBIT $ 9 M
  • EBITDA $ -14 M
  • 60-Month Beta 4.83
  • Price/Sales 0.67
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0100 +19.31%
on 11/24/25
1.2600 -4.37%
on 12/10/25
+0.1350 (+12.62%)
since 11/14/25
3-Month
1.0100 +19.31%
on 11/24/25
2.7900 -56.81%
on 09/29/25
-0.3150 (-20.72%)
since 09/16/25
52-Week
1.0100 +19.31%
on 11/24/25
7.3000 -83.49%
on 12/18/24
-6.2050 (-83.74%)
since 12/16/24

Most Recent Stories

More News
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

Resistance to venetoclax (Venclexta ®  and Venclyxto ® , Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge,...

RDHL : 1.2050 (+1.26%)
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that...

RDHL : 1.2050 (+1.26%)
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

RALEIGH, N.C. and TEL-AVIV, Israel , Nov. 4, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL ) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced...

RDHL : 1.2050 (+1.26%)
RedHill Biopharma Receives Nasdaq Staff Determination Notification

On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for continued...

RDHL : 1.2050 (+1.26%)
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

 Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy

RDHL : 1.2050 (+1.26%)
CPIX : 3.57 (+20.20%)
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business

RDHL : 1.2050 (+1.26%)
RedHill Biopharma Secures $1.8 Million Middle East Deal for Talicia

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

RDHL : 1.2050 (+1.26%)
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

The deal aims to accelerate Talicia's entry into new Middle East markets 

RDHL : 1.2050 (+1.26%)
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

The New York Supreme Court has, on appeal, upheld its original summary judgment ruling in favor of RedHill

RDHL : 1.2050 (+1.26%)
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts

RDHL : 1.2050 (+1.26%)

Business Summary

RedHill Biopharma Ltd. is a specialty biopharmaceutical company, focused on gastrointestinal and infectious diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment is based in Raleigh, NC, and covers all areas relating...

See More

Key Turning Points

3rd Resistance Point 1.2833
2nd Resistance Point 1.2617
1st Resistance Point 1.2333
Last Price 1.2050
1st Support Level 1.1833
2nd Support Level 1.1617
3rd Support Level 1.1333

See More

52-Week High 7.3000
Fibonacci 61.8% 4.8972
Fibonacci 50% 4.1550
Fibonacci 38.2% 3.4128
Last Price 1.2050
52-Week Low 1.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar